Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company headquartered in San Diego, CA, focused on developing and commercializing innovative oncology therapies. The company's core mission is to enhance the efficacy of cancer treatments by targeting the tumor microenvironment, particularly through its lead investigational drug, pegph20. This drug aims to improve the penetration of co-administered cancer therapies into solid tumors, potentially making existing treatments more effective.
Halozyme's proprietary ENHANZE® drug delivery technology platform has garnered significant attention and partnerships with leading pharmaceutical companies such as Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly. This technology facilitates the subcutaneous administration of biologics and small molecule compounds that are traditionally delivered intravenously, potentially allowing for quicker and more convenient therapy delivery.
The company has built a strong foundation of value-driving partnerships and continues to innovate in drug-device combination products using advanced auto-injector technology to improve patient convenience, comfort, and adherence. Halozyme's commercial portfolio includes proprietary products like Hylenex® and XYOSTED®, and ongoing product development in partnership with pharmaceutical companies such as Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Recent achievements highlight Halozyme’s growth and innovation. Notably, the U.S. FDA approved Takeda’s HYQVIA®, co-formulated with ENHANZE®, for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP), underscoring the potential of Halozyme’s technology to enhance treatment efficacy. Another milestone includes the Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis, demonstrating global expansion and acceptance of ENHANZE®-enabled treatments.
Financially, Halozyme continues to show robust growth. The company reported strong revenue and earnings growth in the first quarter of 2024, reaffirming its positive financial guidance for the year. Halozyme also announced a new $750 million share repurchase program, indicating confidence in sustained growth.
Halozyme's efforts in maintaining an extensive patent portfolio, including the recent grant of European Patent No. 4269578 for its ENHANZE® rHuPH20 product, further solidify its market position and prospects for long-term revenue durability. The company's strategic collaborations and commitment to innovative patient solutions make it a significant player in the biopharmaceutical industry.
Halozyme Therapeutics (NASDAQ: HALO) will be represented by Elaine Sun, CFO, in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 3:30 p.m. ET. The event will be accessible via an audio link on the company's website, with a recording available for six months. Halozyme focuses on biopharmaceuticals, utilizing its ENHANZE technology to improve treatment delivery, impacting over 500,000 patients through partnerships with major pharmaceuticals.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host its second quarter 2021 conference call on August 9 at 4:30 p.m. ET. The call will be led by CEO Dr. Helen Torley and will follow the release of financial results for the quarter ending June 30, 2021. Investors can register via a provided link, and the event will be webcast live on Halozyme's corporate site. Halozyme's technology aims to enhance patient experiences, with its solutions impacting over 500,000 patients globally through multiple commercialized products.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen Biotech has received FDA approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone for treating adults with multiple myeloma after prior therapy. This marks the sixth indication for DARZALEX FASPRO® in multiple myeloma treatment. The approval is backed by positive results from the Phase 3 APOLLO study, highlighting improved progression-free survival. Halozyme's ENHANZE® drug delivery technology underpins this therapy, enhancing patient treatment experiences through subcutaneous delivery.
Halozyme Therapeutics (NASDAQ: HALO) announced that the European Commission granted Janssen Pharmaceutical marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX® SC. This includes an authorization for treating adults with newly diagnosed systemic light-chain amyloidosis (first approved therapy for AL amyloidosis in Europe) and for adults with multiple myeloma who are lenalidomide refractory. These approvals enhance treatment options for specific patient groups in Europe, furthering Halozyme's commitment to improving patient outcomes.
ViiV Healthcare and Halozyme Therapeutics have entered a global collaboration that grants ViiV exclusive access to Halozyme's ENHANZE® drug delivery technology for HIV treatments. ViiV will pay $40 million upfront, with potential milestone payments totaling up to $175 million per target. This partnership aims to enhance the development of long-acting HIV therapies, reducing the frequency of medication. The PH20 enzyme allows for efficient large-volume subcutaneous injections, potentially addressing treatment challenges for patients and improving their experience.
ViiV Healthcare and Halozyme Therapeutics have formed a collaboration to utilize Halozyme's ENHANZE® drug delivery technology for HIV treatment and prevention. ViiV will pay Halozyme $40 million upfront, with potential future payments totaling $175 million based on development milestones. This partnership aims to develop ultra-long acting HIV medicines, reducing the treatment burden for patients. Halozyme's enzyme technology enables rapid delivery of large volumes of medication, potentially extending dosing intervals beyond current standards. The collaboration could lead to innovative options in HIV therapies.
Halozyme Therapeutics (NASDAQ: HALO) announced presentations of collaborative studies utilizing ENHANZE® technology at the 2021 ASCO Annual Meeting from June 4-8. Key studies included Phase 3 results for AL amyloidosis treatment and preliminary analyses of nivolumab. Highlights also featured cost analysis for a fixed-dose combination treatment for HER2-positive breast cancer. Halozyme's ENHANZE® technology aims to enhance patient treatment experiences, and the company has licensed this technology to major pharmaceutical firms. The press release emphasizes ongoing development and collaboration, impacting potential revenue through milestones and royalties.
Halozyme Therapeutics (NASDAQ: HALO) announced its participation in two upcoming virtual investor conferences. The first is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, featuring Dr. Helen Torley at 11:20 a.m. ET. The second is the JMP Securities Life Sciences Conference on June 17, 2021, with Elaine Sun at 3:00 p.m. ET. Live webcasts will be available on their website, along with archived recordings for a month after each event.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen received positive opinions from the EMA's CHMP for expanding DARZALEX® (daratumumab) subcutaneous formulation to treat AL amyloidosis and relapsed multiple myeloma. The first opinion supports the use of DARZALEX® with cyclophosphamide, bortezomib, and dexamethasone for newly diagnosed AL amyloidosis patients. The second opinion recommends its use with pomalidomide and dexamethasone for specific multiple myeloma patients. These recommendations will be reviewed by the European Commission for final approval.
Halozyme Therapeutics (NASDAQ: HALO) reported strong Q1 2021 results with revenues of $89 million, a 250% increase from $25.4 million in Q1 2020. Key drivers included $30 million in milestone revenues from Janssen and Bristol Myers Squibb, and a 119% rise in royalty revenue from subcutaneous DARZALEX®. Operating income reached $50.7 million compared to a loss of $3.2 million a year earlier. The company expects 2021 revenues between $375 million and $395 million, reflecting 40%-48% growth. Cash and equivalents totaled $764.3 million at quarter-end.
FAQ
What is the current stock price of Halozyme Therapeutics (HALO)?
What is the market cap of Halozyme Therapeutics (HALO)?
What is Halozyme Therapeutics' main focus?
What is the ENHANZE® technology?
Who are Halozyme's key partners?
What recent approvals have Halozyme's technologies received?
What are some of Halozyme's proprietary products?
Where is Halozyme headquartered?
How does Halozyme's ENHANZE® technology benefit patients?
What is the significance of Halozyme's recent European patent grant?
What financial outlook did Halozyme recently provide?
What is pegph20?
